. The company’s pipeline consists of four clinical-stage therapies. Its most advanced drug applicant is ROS1 inhibitor taletrectinib for treating lung most cancers. Nuvation is finishing two period 2 pivotal reports on taletrectinib. On April 11, immediately after publishing a number of tweets essential in the company, Musk announced https://financefeeds.com/global-fx-market-summary-us-economic-data-geopolitical-tensions-copyright-regulations-21-march-2025/